BoneSwift™ Injectable Bone Graft Material — Limb Clinical Case Series (Part 1)
BoneSwift™, the injectable bone graft material independently developed by Medgen Life Science, has obtained both the China NMPA Class III medical device registration certificate and the Vietnam Class D (highest level) medical device registration certificate, covering dual indications for limb bone defect repair and spinal bone defect repair.
This series presents real clinical cases demonstrating the performance of BoneSwift™ in limb bone defect repair.
Core Product Advantages
Natural Biomimetic Material
BoneSwift™ is derived from natural porcine cancellous bone, retaining the complete natural trabecular bone structure. This facilitates rapid cell attachment and proliferation, simulates the human skeletal microenvironment, provides excellent osteoinductive properties, and accelerates the clinical bone healing process.
Pre-filled Ready-to-Use Design
The pre-filled syringe design enables direct injection and filling without on-site mixing. The material is freely moldable with excellent extensibility, significantly reducing surgical time and minimizing intraoperative contamination risk.
Dual Certification, Dual Indications
- China NMPA Class III medical device registration certificate
- Vietnam Class D (highest level) medical device registration certificate
- Indications covering both limb bone defect repair and spinal bone defect repair
BoneSwift™ injectable bone graft material is now commercially available nationwide. Medical institutions are welcome to inquire about clinical trials and product evaluation.